Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
Adolescent
Adult
Child
Child, Preschool
Female
Genetic Association Studies
Genetic Predisposition to Disease
Heterozygote
Humans
Infant
Learning Disabilities
/ genetics
Male
Mutation, Missense
/ genetics
Neurofibroma, Plexiform
/ genetics
Neurofibromatosis 1
/ genetics
Neurofibromin 1
/ genetics
Sequence Deletion
Young Adult
NF1
genotype–phenotype correlation
learning difficulties
neurofibroma
p.Met992del
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
29
05
2018
accepted:
31
07
2018
pubmed:
8
9
2018
medline:
19
6
2019
entrez:
8
9
2018
Statut:
ppublish
Résumé
Neurofibromatosis type 1 (NF1) is characterized by a highly variable clinical presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous neurofibromas. Exceptions are individuals heterozygous for the NF1 in-frame deletion, c.2970_2972del (p.Met992del), associated with a mild phenotype without any externally visible tumors. A total of 135 individuals from 103 unrelated families, all carrying the constitutional NF1 p.Met992del pathogenic variant and clinically assessed using the same standardized phenotypic checklist form, were included in this study. None of the individuals had externally visible plexiform or histopathologically confirmed cutaneous or subcutaneous neurofibromas. We did not identify any complications, such as symptomatic optic pathway gliomas (OPGs) or symptomatic spinal neurofibromas; however, 4.8% of individuals had nonoptic brain tumors, mostly low-grade and asymptomatic, and 38.8% had cognitive impairment/learning disabilities. In an individual with the NF1 constitutional c.2970_2972del and three astrocytomas, we provided proof that all were NF1-associated tumors given loss of heterozygosity at three intragenic NF1 microsatellite markers and c.2970_2972del. We demonstrate that individuals with the NF1 p.Met992del pathogenic variant have a mild NF1 phenotype lacking clinically suspected plexiform, cutaneous, or subcutaneous neurofibromas. However, learning difficulties are clearly part of the phenotypic presentation in these individuals and will require specialized care.
Identifiants
pubmed: 30190611
doi: 10.1038/s41436-018-0269-0
pii: S1098-3600(21)00966-7
pmc: PMC6752285
doi:
Substances chimiques
Neurofibromin 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-876Commentaires et corrections
Type : ErratumIn
Références
Eur J Intern Med. 2014 Jul;25(6):506-10
pubmed: 24784952
Pediatr Radiol. 1996 Jul;26(7):478-87
pubmed: 8662066
Hum Mutat. 2015 Nov;36(11):1052-63
pubmed: 26178382
Am J Med Genet. 2000 May 15;92(2):132-5
pubmed: 10797438
J Invest Dermatol. 2015 Mar;135(3):904-906
pubmed: 25354145
Eur J Hum Genet. 2015 Aug;23(8):1068-71
pubmed: 25370043
JCO Precis Oncol. 2017;2017:
pubmed: 29938249
Am J Med Genet A. 2004 Jun 15;127A(3):224-9
pubmed: 15150770
Arch Dis Child. 1998 May;78(5):408-12
pubmed: 9659085
Brain. 1988 Dec;111 ( Pt 6):1355-81
pubmed: 3145091
Neurology. 2005 Jul 26;65(2):205-11
pubmed: 16043787
Am J Med Genet. 2000 Nov 13;95(2):108-17
pubmed: 11078559
J Med Genet. 1989 Nov;26(11):704-11
pubmed: 2511318
Orphanet J Rare Dis. 2017 Feb 15;12(1):34
pubmed: 28202035
J Med Genet. 2007 Jul;44(7):463-6
pubmed: 17327286
Hum Genet. 2017 Apr;136(4):349-376
pubmed: 28213670
Eur J Hum Genet. 2015 Nov;23(11):1460-1
pubmed: 25966637
Acta Paediatr. 2009 Apr;98(4):693-8
pubmed: 19120036
Hum Mutat. 2012 Nov;33(11):1538-46
pubmed: 22753041
Neuroradiology. 1999 Sep;41(9):625-9
pubmed: 10525761
PLoS One. 2012;7(4):e35711
pubmed: 22558206
Orphanet J Rare Dis. 2011 May 04;6:18
pubmed: 21542925
Am J Med Genet. 1997 May 16;70(2):138-43
pubmed: 9128932
Oncologist. 2012;17(1):101-16
pubmed: 22240541
Am J Med Genet A. 2014 Mar;164A(3):579-87
pubmed: 24357598
Oncologist. 2000;5(6):477-85
pubmed: 11110599
Clin Cancer Res. 2017 Jun 15;23(12):e46-e53
pubmed: 28620004
J Med Genet. 1999 Mar;36(3):197-203
pubmed: 10204844
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Curr Probl Pediatr Adolesc Health Care. 2012 Apr;42(4):80-103
pubmed: 22433905
J Pediatr. 1994 Jul;125(1):63-6
pubmed: 8021787
Hum Mutat. 2010 Jul;31(7):840-50
pubmed: 20506139
Eur J Paediatr Neurol. 2016 Mar;20(2):275-281
pubmed: 26774135
J Med Genet. 2002 May;39(5):311-4
pubmed: 12011145
Am J Hum Genet. 2018 Jan 4;102(1):69-87
pubmed: 29290338
Am J Hum Genet. 2007 Jan;80(1):140-51
pubmed: 17160901
Neurology. 1998 Jun;50(6):1755-60
pubmed: 9633723
Am J Med Genet A. 2005 Jan 1;132A(1):49-53
pubmed: 15523617
J Med Genet. 2007 Feb;44(2):81-8
pubmed: 17105749
J Biol Chem. 2016 Feb 12;291(7):3124-34
pubmed: 26635368
Case Rep Neurol. 2011 Apr 11;3:86-90
pubmed: 21532985
Arch Neurol. 1988 May;45(5):575-8
pubmed: 3128965
J Med Genet. 1989 Nov;26(11):712-21
pubmed: 2511319